Overall Recruitment Status: Completed

A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers

Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly

Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly

Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer

Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma

An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome

Study of Lanreotide Autogel 120mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour

Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients

Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours

Effects of Triptorelin Pamoate in Children With Precocious Puberty – Follow up Study